Cite
Hammer F, Buehling SS, Masyout J, et al. Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochem Biophys Res Commun. 2021;582:28-34doi: 10.1016/j.bbrc.2021.10.023.
Hammer, F., Buehling, S. S., Masyout, J., Malzahn, U., Hauser, T., Auer, T., Grebe, S., Feger, M., Tuffaha, R., Degenhart, G., Lang, F., Pasch, A., Alesutan, I., Wanner, C., Krane, V., & Voelkl, J. (2021). Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochemical and biophysical research communications, 58228-34. https://doi.org/10.1016/j.bbrc.2021.10.023
Hammer, Fabian, et al. "Protective effects of spironolactone on vascular calcification in chronic kidney disease." Biochemical and biophysical research communications vol. 582 (2021): 28-34. doi: https://doi.org/10.1016/j.bbrc.2021.10.023
Hammer F, Buehling SS, Masyout J, Malzahn U, Hauser T, Auer T, Grebe S, Feger M, Tuffaha R, Degenhart G, Lang F, Pasch A, Alesutan I, Wanner C, Krane V, Voelkl J. Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochem Biophys Res Commun. 2021 Dec 10;582:28-34. doi: 10.1016/j.bbrc.2021.10.023. Epub 2021 Oct 10. PMID: 34678593.
Copy
Download .nbib